Fosamax (alendronate) is now approved for the treatment and prevention of osteoporosis caused by chronic glucocorticoids
August 1999
Fosamax (alendronate) is now approved for the treatment and prevention of osteoporosis caused by chronic glucocorticoids.
This new indication is for men or women who take the equivalent of 7.5 mg/day or more of prednisone.
Patients on chronic steroids for rheumatoid arthritis, asthma, etc, are especially vulnerable to bone loss and fractures.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive